ChemExpress Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
4,195
- Stock Symbol
-
688131
- Investments
-
7
- Share Price
-
$14.32
- (As of Thursday Closing)
ChemExpress General Information
Description
Shanghai Haoyuan Chemexpress Co Ltd focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. The company's comprehensive CRO & CDMO platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. It is a one-stop service platform to support client's projects from early drug discovery, process development to commercialization. The company is committed to delivering high-quality products and CMC services to clients across the entire life cycle of drug development.
Contact Information
Website
www.chemexpress.comCorporate Office
- No. 3 Building, No. 1999, Zhangheng Road
- Pudong New Area
- Shanghai, 201203
- China
Corporate Office
- No. 3 Building, No. 1999, Zhangheng Road
- Pudong New Area
- Shanghai, 201203
- China
ChemExpress Stock Performance
As of 12-Nov-2026, ChemExpress’s stock price is $14.32. Its current market cap is $3.05B with 213M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $14.32 | $14.30 | $8.66 - $16.58 | $3.05B | 213M | 5.05M | $0.21 |
ChemExpress Financials Summary
As of 30-Sep-2026, ChemExpress has a trailing 12-month revenue of $503M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,285,699 | 2,287,696 | 1,143,119 | 1,201,935 |
| Revenue | 502,577 | 400,051 | 316,381 | 265,736 |
| EBITDA | 56,103 | 67,622 | 59,220 | 38,433 |
| Net Income | 45,261 | 33,347 | 28,094 | 18,014 |
| Total Assets | 1,031,325 | 899,606 | 754,092 | 591,401 |
| Total Debt | 364,475 | 319,402 | 261,079 | 147,750 |
ChemExpress Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ChemExpress Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ChemExpress Patents
ChemExpress Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024092420-A1 | Preparation method for ((2r,7as)-2-fluorohexahydro-1h-pyrrolizin-7a-yl)methanol | Inactive | 31-Oct-2022 | ||
| WO-2024045255-A1 | Tegoprazan crystal form b and preparation method therefor | Inactive | 30-Aug-2022 | ||
| WO-2024027013-A1 | Crystal form ii of elobixibat and preparation method therefor | Inactive | 02-Aug-2022 | ||
| WO-2024021261-A1 | Method for preparing eribulin intermediate | Inactive | 29-Jul-2022 | ||
| EP-4520760-A1 | Lurbinectedin crystal form and method for preparing same | Pending | 08-Apr-2022 | C07D515/22 |
ChemExpress Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ChemExpress Investments & Acquisitions (7)
ChemExpress’s most recent deal was a Early Stage VC with Chongqing Haoyuan Biopharmaceutical. The deal was made on 17-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Chongqing Haoyuan Biopharmaceutical | 17-Apr-2024 | Early Stage VC | Drug Discovery | ||
| Chongqing Haoyuan Biopharmaceutical | 04-Dec-2023 | Seed Round | Drug Discovery | ||
| Tarapeutics | 03-Jan-2023 | Early Stage VC | Drug Discovery | ||
| 2Y-Chem | 16-Dec-2022 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Burgeon Therapeutics | 22-Sep-2022 | Early Stage VC | Drug Discovery |
ChemExpress ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
23.49 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Chemicals
Industry
of 502
Rank
Percentile
Commodity Chemicals
Subindustry
of 207
Rank
Percentile
ChemExpress Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| 2Y-Chem | Shanghai, China | 2003 |
ChemExpress FAQs
-
When was ChemExpress founded?
ChemExpress was founded in 2006.
-
Where is ChemExpress headquartered?
ChemExpress is headquartered in Shanghai, China.
-
What is the size of ChemExpress?
ChemExpress has 4,195 total employees.
-
What industry is ChemExpress in?
ChemExpress’s primary industry is Drug Discovery.
-
Is ChemExpress a private or public company?
ChemExpress is a Public company.
-
What is ChemExpress’s stock symbol?
The ticker symbol for ChemExpress is 688131.
-
What is the current stock price of ChemExpress?
As of 12-Nov-2026 the stock price of ChemExpress is $14.32.
-
What is the current market cap of ChemExpress?
The current market capitalization of ChemExpress is $3.05B.
-
What is ChemExpress’s current revenue?
The trailing twelve month revenue for ChemExpress is $503M.
-
What is ChemExpress’s annual earnings per share (EPS)?
ChemExpress’s EPS for 12 months was $0.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
